Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Review ArticleTeaching Case Studies

The Evaluation of Cardiac Sarcoidosis with 18F-FDG PET

Zaid Al-Faham, Prashant Jolepalem and Ching Yee Oliver Wong
Journal of Nuclear Medicine Technology June 2016, 44 (2) 92-93; DOI: https://doi.org/10.2967/jnmt.115.158857
Zaid Al-Faham
Department of Diagnostic Radiology and Molecular Imaging, William Beaumont School of Medicine and Beaumont Health System, Oakland University, Royal Oak, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prashant Jolepalem
Department of Diagnostic Radiology and Molecular Imaging, William Beaumont School of Medicine and Beaumont Health System, Oakland University, Royal Oak, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ching Yee Oliver Wong
Department of Diagnostic Radiology and Molecular Imaging, William Beaumont School of Medicine and Beaumont Health System, Oakland University, Royal Oak, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Cardiac involvement in sarcoidosis is associated with poor prognosis. 18F-FDG PET can detect the presence of cardiac sarcoidosis, assess disease activity, and serve as a means to monitor treatment response in patients with cardiac sarcoidosis.

  • 18F-FDG PET
  • myocardial sarcoidosis
  • cardiac MR imaging

Cardiac involvement occurs in 20%–30% of patients who had systemic sarcoidosis as shown in pathology examinations and is associated with poor prognosis (1,2). Although myocardial granulomas can be identified in almost 25%–79% of autopsy examinations, only 25% of all patients with sarcoidosis have clinical manifestations of cardiac involvement (1). In this report, 18F-FDG PET helped in diagnosing a patient with suspected cardiac sarcoidosis, classifying the disease activity, and monitoring the response to treatment.

CASE REPORT

A 68-y-old man with a history of cutaneous sarcoidosis presented to the cardiology clinic with progressive dyspnea. Physical examination revealed +4-pitting edema. Electrocardiography showed complete heart block. The results of cardiac MR imaging suggested an infiltrative process. The patient was instructed to take a high-fat low-carbohydrate diet the day before imaging, without an additional overnight fast. With a baseline blood glucose level of 93 mg/dL, the patient was injected with 3.94 Bq (10.67 mCi) of 18F-FDG, and after a 1-h delay, multiple metabolic tomographic images of the myocardium were obtained. The 13N-ammonia perfusion images (Fig. 1, bottom) demonstrated defects in the mid to basal inferior wall, basal anterior walls, and anteroseptal and inferoseptal areas, as indicated by a correspondingly increased level of 18F-FDG uptake in these regions. This finding was consistent with active sarcoid infiltration of the myocardium. The calculated ejection fraction was 24%. The patient completed a 6-mo trial of high-dose steroids, after which a follow-up myocardial PET study (Fig. 2) demonstrated moderate improvement of the perfusion defects (whereas the 18F-FDG portion demonstrated only blood-pool activity without myocardial trapping). The ejection fraction improved to 37%. These findings indicated an excellent response to treatment of the existing inflammation, although clinical improvement depends on the extent of previous damage.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Perfusion images demonstrating defects in mid to basal inferior wall, basal anterior walls, and anteroseptal and inferoseptal areas, as indicated by correspondingly increased 18F-FDG uptake in these regions.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Improvement of perfusion defects as indicated by only blood-pool activity being seen on 18F-FDG images.

DISCUSSION

Cardiac sarcoidosis represents the cause of death in 13%–25% of fatal cases of sarcoidosis (1). A definitive diagnosis of cardiac sarcoidosis can be made by endomyocardial biopsy, with sensitivity being less than 20% (2). For a definitive diagnosis and management, all patients will likely benefit from an echocardiogram and either cardiac MR imaging or 18F-FDG PET (1). Cardiac MR imaging is usually performed as the initial test in patients with suspected cardiac sarcoidosis. Gadolinium-enhanced cardiac MR imaging with delayed imaging has the benefit of high sensitivity and spatial resolution without radiation exposure. If the MR results are negative, 18F-FDG PET can be avoided. If the MR results suggest cardiac involvement, 18F-FDG PET imaging may be performed to establish baseline disease activity, assess the need for initiation of medical therapy, and monitor response to treatment over time. In patients with contraindications to cardiac MR imaging, 18F-FDG PET can be used as the first-line imaging method (1). Usually, cardiac MR imaging shows scarring, and thus chronic disease, whereas 18F-FDG PET identifies active involvement. Typical radionuclide protocols for imaging cardiac sarcoidosis include 18F-FDG PET for imaging inflammation combined with SPECT or PET myocardial perfusion imaging (1).

The myocardial perfusion assessment can be performed with 99mTc, 201Tl, 13N-ammonia, or 82Rb-based radiotracers using standard protocols. Attenuation correction should be applied to SPECT myocardial perfusion imaging whenever possible. In the absence of coronary artery abnormalities, perfusion defects seen on PET scanning in a patient with sarcoidosis strongly suggest that the heart is involved (2). One way to describe the pattern in cardiac sarcoidosis on PET scans is to compare the degree of perfusion abnormality with the intensity of 18F-FDG uptake: normal (normal perfusion/normal 18F-FDG), early stage (mild perfusion defect/increased 18F-FDG), progressive stage (moderate perfusion defect/increased 18F-FDG), progressive myocardial impairment stage (severe perfusion defect/increased 18F-FDG), and fibrosis stage (severe perfusion defect/minimal or no 18F-FDG uptake) (1). We used this method, and the results were descriptive of the progressive myocardial impairment stage (Fig. 1). Our patient showed clinical improvement after 6 mo of treatment, and the PET findings resolved. 18F-FDG uptake was consistent with subsided inflammation, although clinical improvement (Fig. 2) is ultimately limited by the previous damage.

CONCLUSION

18F-FDG PET can detect the presence of cardiac sarcoidosis, assess disease activity, and monitor treatment response in patients.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Aug. 13, 2015.

REFERENCES

  1. 1.↵
    1. Skali H,
    2. Schulman AR,
    3. Dorbala S
    . 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep. 2013;15:352.
    OpenUrlCrossRef
  2. 2.↵
    1. Sekhri V,
    2. Sanal S,
    3. Delorenzo LJ,
    4. Aronow WS,
    5. Maguire GP
    . Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;7:546–554.
    OpenUrlPubMed
  • Received for publication April 6, 2015.
  • Accepted for publication July 1, 2015.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 44 (2)
Journal of Nuclear Medicine Technology
Vol. 44, Issue 2
June 1, 2016
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Evaluation of Cardiac Sarcoidosis with 18F-FDG PET
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
The Evaluation of Cardiac Sarcoidosis with 18F-FDG PET
Zaid Al-Faham, Prashant Jolepalem, Ching Yee Oliver Wong
Journal of Nuclear Medicine Technology Jun 2016, 44 (2) 92-93; DOI: 10.2967/jnmt.115.158857

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Evaluation of Cardiac Sarcoidosis with 18F-FDG PET
Zaid Al-Faham, Prashant Jolepalem, Ching Yee Oliver Wong
Journal of Nuclear Medicine Technology Jun 2016, 44 (2) 92-93; DOI: 10.2967/jnmt.115.158857
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • CASE REPORT
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • High-Sensitivity Troponin Elevation in a Young Woman with Typical Chest Pain: The Heart of the Matter
  • Pulmonary Adenocarcinoma Revealed by Parathyroid Scintigraphy: An Incidental Case to Remember
  • Prominent Right Ventricular Tracer Uptake: A Harbinger of Multivessel Coronary Artery Disease
Show more Teaching Case Studies

Similar Articles

Keywords

  • 18F-FDG PET
  • Myocardial sarcoidosis
  • cardiac MR imaging
SNMMI

© 2025 SNMMI

Powered by HighWire